ABL-001产品是ABL-001 is a potent allosteric inhibitor of BCR-ABL. ABL001 binds to the myristoyl pocket of ABL1 and induces the formation of an inactive kinase conformation. ABL001 prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of CML (chronic myeloid leukemia).